Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$4.89
-1.9%
$4.04
$2.12
$5.80
$487.15M1.821.62 million shs837,650 shs
Celularity, Inc. stock logo
CELU
Celularity
$2.34
+3.3%
$3.01
$1.00
$5.22
$62.32M0.81169,089 shs125,160 shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$7.84
+5.3%
$5.26
$2.86
$13.93
$537.95M1.92897,039 shs1.43 million shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$3.19
-0.8%
$3.14
$2.19
$22.01
$343.66M0.623.63 million shs1.16 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-0.60%+30.03%+27.69%+46.04%+6.18%
Celularity, Inc. stock logo
CELU
Celularity
+7.11%-11.37%-30.25%+25.56%-17.52%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-1.85%+14.99%+60.34%+82.35%-40.43%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-1.53%-0.93%+12.24%+5.94%-83.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$4.89
-1.9%
$4.04
$2.12
$5.80
$487.15M1.821.62 million shs837,650 shs
Celularity, Inc. stock logo
CELU
Celularity
$2.34
+3.3%
$3.01
$1.00
$5.22
$62.32M0.81169,089 shs125,160 shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$7.84
+5.3%
$5.26
$2.86
$13.93
$537.95M1.92897,039 shs1.43 million shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$3.19
-0.8%
$3.14
$2.19
$22.01
$343.66M0.623.63 million shs1.16 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-0.60%+30.03%+27.69%+46.04%+6.18%
Celularity, Inc. stock logo
CELU
Celularity
+7.11%-11.37%-30.25%+25.56%-17.52%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-1.85%+14.99%+60.34%+82.35%-40.43%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-1.53%-0.93%+12.24%+5.94%-83.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$10.29110.56% Upside
Celularity, Inc. stock logo
CELU
Celularity
3.00
Buy$6.00156.96% Upside
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
2.67
Moderate Buy$24.00206.20% Upside
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
2.41
Hold$16.73425.38% Upside

Current Analyst Ratings Breakdown

Latest CELU, AQST, OLMA, and RCKT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2025
Celularity, Inc. stock logo
CELU
Celularity
WBB Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$6.00
9/8/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$7.00 ➝ $8.00
9/3/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/3/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$22.00
8/20/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$4.00 ➝ $10.00
8/20/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$11.00
8/18/2025
Celularity, Inc. stock logo
CELU
Celularity
WBB Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageModerate Buy$6.00
8/14/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$28.00 ➝ $29.00
8/13/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
8/12/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$20.00 ➝ $21.00
8/11/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$44.13M11.04N/AN/A($0.66) per share-7.40
Celularity, Inc. stock logo
CELU
Celularity
$54.22M1.15N/AN/A$0.37 per share6.31
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/A$7.14 per shareN/A
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/A$5.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$44.14M-$0.70N/AN/AN/A-147.38%N/A-63.87%11/3/2025 (Estimated)
Celularity, Inc. stock logo
CELU
Celularity
-$57.89M-$3.18N/AN/A-165.22%-459.57%-57.71%11/5/2025 (Estimated)
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)

Latest CELU, AQST, OLMA, and RCKT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/29/2025Q1 2025
Celularity, Inc. stock logo
CELU
Celularity
N/A-$1.02N/A-$1.02N/A$5.74 million
8/11/2025Q2 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.18-$0.14+$0.04-$0.14$11.32 million$10.00 million
8/11/2025Q2 2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$0.43-$0.51-$0.08-$0.51N/AN/A
8/7/2025Q2 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.57-$0.59-$0.02-$0.62$4.36 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
Celularity, Inc. stock logo
CELU
Celularity
N/AN/AN/AN/AN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/AN/A
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
3.53
3.18
Celularity, Inc. stock logo
CELU
Celularity
4.07
0.25
0.19
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
0.01
11.09
11.09
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
0.05
6.39
6.39

Institutional Ownership

CompanyInstitutional Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
Celularity, Inc. stock logo
CELU
Celularity
19.02%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
91.78%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
98.39%

Insider Ownership

CompanyInsider Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
7.85%
Celularity, Inc. stock logo
CELU
Celularity
22.10%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
16.36%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
24.76%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
16099.72 million91.90 millionOptionable
Celularity, Inc. stock logo
CELU
Celularity
22026.69 million20.79 millionOptionable
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
7068.63 million57.41 millionOptionable
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
240107.90 million81.19 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$4.88 -0.10 (-1.91%)
Closing price 03:59 PM Eastern
Extended Trading
$4.88 -0.01 (-0.20%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Celularity stock logo

Celularity NASDAQ:CELU

$2.34 +0.08 (+3.32%)
Closing price 03:58 PM Eastern
Extended Trading
$2.35 +0.01 (+0.43%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Olema Pharmaceuticals stock logo

Olema Pharmaceuticals NASDAQ:OLMA

$7.84 +0.40 (+5.35%)
Closing price 03:59 PM Eastern
Extended Trading
$7.78 -0.06 (-0.80%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Rocket Pharmaceuticals stock logo

Rocket Pharmaceuticals NASDAQ:RCKT

$3.18 -0.03 (-0.78%)
Closing price 03:59 PM Eastern
Extended Trading
$3.22 +0.04 (+1.13%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.